a product developed in partnership with myeloid cancer experts based on the latest WHO guidance,¹ combining expert-led panel design with hybridisation-based enrichment for unparalleled uniformity and depth of coverage.
an RNA-based, partner gene-agnostic panel, detecting 30 common myeloid fusions and novel fusion partners in a single cost-efficient assay.
a full assay and software solution with streamlined library prep and intuitive, complimentary data analysis software.

The RNA-based SureSeq^TM Myeloid Fusion Panel targets single key fusion partners, allowing for the identification of driver-genes with multiple partners (e.g. KMT2A) and novel or rare fusions, supporting research into myeloid cancer classification and progression. This unique approach further serves to minimise the panel size, lowering sequencing costs and enabling increased depth of coverage for more sensitive results. Additionally, the panel enables the identification of gene expression changes in MECOM, supporting the identification of GATA2-MECOM (inv(3)(q21.3q26.2) and RPN1-MECOM (inv(3)(q21q26).

Gene targets

RBM15-MKL1 t(1;22)(p13.3;q13.3)	KMT2A-ELL t(11;19)(q23;p13.1)	FUS-ERG t(16;21)(p11.2;q22.2)	FGFR1-ZMYM2 t(8;13)(p11;q12)
GATA2-MECOM* (GATA2-EVI1)* inv(3)(q21.3q26.2) *via MECOM* overexpression**	*KMT2A-MLLT1* (ENL) t(11;19) (q23;p13.3)	CBFB-MYH11 inv(16)(p13.1q22)	FIP1L1-PDGFRA del(4)(q12q12)
RPN1-MECOM* (RPN1-EVI1)* inv(3)(q21q26) *via MECOM* overexpression**	KMT2A-AF6 (MLLT4; AFDN) t(6;11)(q27;q23)	RUNX1-RUNX1T1 (AML1-ETO) t(8;21)(q22;q22.1)	PDGFRB-EBF1 del(5)(q32q33)
DEK-*NUP214* (DEK-CAN) t(6;9)(p23;q34.1)	KMT2A-MLLT11 t(1;11)(q21;q23)	ETV6-*RUNX1* (TEL-AML1) t(12;21)(p13;q22)	PDGFRB-TNIP1 t(5;5)(q32;q33)
NUP98-NSD1 t(5;11)(q35.2;p15.4)	KMT2A-NEBL t(10;11)(p12;q23)	*RUNX1-MECOM* (AML1-EV1L) t(3;21)(q26.2;q22)	PDGFRB-ATF7IP t(5;12)(q33;p13)
NUP98-HOXA9 t(7;11)(p15.4;p15.2)	PML-RARα t(15;17)(q24;q21)	BCR-ABL1 t(9;22)(q34.1;q11.2)	PDGFRB-ETV6 t(5;12)(q33;p13)
PICALM-MLLT10 t(10;11)(p12.3;q14.2)	KAT6A-CREBBP t(8;16)(p11.2;p13.3)	NPM1-MLF1 t(3;5)(q25.1;q35.1)
*KMT2A-MLLT3* (AF9) t(9;11)(p21.3;q23.3)	PCM1-JAK2 t(8;9)(p22;p24)	*FGFR1-BCR* t(8;22)(p11;q11)

More details

Figure 1: Consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls. MECOM expression is normalised to the expression of housekeeping genes and expression values are calculated as counts per million (CPM). ‘Research (+)’ refers to research sample containing GATA2-MECOM (inv(3)(q21.3q26.2)). ‘Commercial (+)’ refers to Universal Human Reference RNA (UHRR) used as positive control. ‘Research (-)’ refers to blood extracted RNA with no GATA2-MECOM (inv(3) (q21.3q26.2)). ‘Commercial (-)’ refers to normal human lymphocyte RNA used as negative control. Error bars represent standard deviation.

Figure 2: Interpret enables identification of [A B] canonical fusions such as KMT2A-AFDN (MLLT4) and KMT2A-MLLT3 as well as [C D] novel fusions such as KMT2A-MLLT10 and KMT2A-MLLT6, emphasising the partner gene agnostic capability for fusion detection.

Haematological NGS panels

View all NGS library preparation kits & reagents

References

[1] Khoury et al. Leukemia. 2022 ;36:1703-19.

Disclaimer

SureSeq^TM For Research Use Only, not for use in diagnostic procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability.

Manufacturer and Trademarks: SureSeq^TM(Oxford Gene Technology IP Limited)

Technical specifications

Technical information

Feature	Specification
Capabilities	Fusion and MECOM expression detection
Number of Fusions	30
Panel Size	61 kb
RNA input recommended	200–500 ng good quality RNA (RIN ≥7)
Sample Source	Whole blood, bone marrow extracted RNA

Ordering information

Product	Contents	Cat. No.
SureSeq Myeloid Fusion Complete NGS Workflow Solution V2 (24)	Enrichment baits sufficient for 3 x 8-sample pools. Bundle of 1 x Double-Stranded cDNA Synthesis Kit (24). 1 x Universal Library Preparation Kit (24) containing PCR primers and enzymes. 1 x Universal Hybridisation & Wash Kit V2 (24). 1 x Pre-PCR Universal Bead Kit (24). 1 x Post-PCR Universal Bead Kit (24). 1 x Universal Index Adapter Kit (24). Interpret NGS Analysis Software	890001-24
SureSeq Myeloid Fusion Complete NGS Workflow Solution V2 (96)	Enrichment baits sufficient for 12 x 8-sample pools. Bundle of 1 x Double-Stranded cDNA Synthesis Kit (96). 1 x Universal Library Preparation Kit (96) containing PCR primers and enzymes. 1 x Universal Hybridisation & Wash Kit V2 (96). 1 x Pre-PCR Universal Bead Kit (96). 1 x Post-PCR Universal Bead Kit (96). 1 x Universal Index Adapter Kit (96). Interpret NGS Analysis Software	890001-96
SureSeq Myeloid Fusion Panel (24)	Enrichment baits sufficient for 3 x 8-sample pools. Interpret NGS Analysis Software	880001-24
SureSeq Myeloid Fusion Panel (96)	Enrichment baits sufficient for 12 x 8-sample pools. Interpret NGS Analysis Software	880001-96
SureSeq Double-Stranded cDNA Synthesis Kit (24)	Kit for conversion of 24 RNA samples to cDNA samples	880500-24
SureSeq Double-Stranded cDNA Synthesis Kit (96)	Kit for conversion of 96 RNA samples to cDNA samples	880500-96
Universal NGS Workflow Solution V2 (24)	Bundle of 1 x Universal Library Preparation Kit (24) containing, PCR primers and enzymes, 1 x Universal Hybridisation & Wash Kit V2 (24). Pre-PCR Universal Bead Kit (24). Post-PCR Universal Bead Kit (24). 1 x Universal Index Adapter Kit (24)	770510-24
Universal NGS Workflow Solution V2 (96)	Bundle of 1 x Universal Library Preparation Kit (96) containing, PCR primers and enzymes, 1 x Universal Hybridisation & Wash Kit V2 (96). Pre-PCR Universal Bead Kit (96). Post-PCR Universal Bead Kit (96). 1 x Universal Index Adapter Kit (96)	770510-96